Return Peptide Library
Enisamitide
BLevel 1 evidenceEnisamipide
GLP-1 and incretin receptor agonists
Basic Information
Categories
Incretin mimetics
Overview
Roche/Genentech dual GLP-1/GIP receptor agonist: 22.5% weight loss in Phase II, 48-week trial.
Efficacy Rating
GLP-1/GIP agonist, weight loss
Evidence Level
Grade B
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
Ribaputide
Ribupatide
CGLP-1 and incretin receptor agonists
GLP-1/GIP agonist, weight loss
Albiglutide
Albiglutide
BGLP-1 and incretin receptor agonists
GLP-1 RA, type 2 diabetes mellitus, discontinued
Semaglutide
Ecenoglutide
BGLP-1 and incretin receptor agonists
GLP-1, weight loss, biased agonist
Exenatide
Exenatide
BGLP-1 and incretin receptor agonists
Metabolic health, FDA-approved, GLP-1
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.